Icatibant
Firazyr (icatibant) is a protein pharmaceutical. Icatibant was first approved as Firazyr on 2008-07-11. It is used to treat hereditary angioedemas in the USA. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against B2 bradykinin receptor. In addition, it is known to target B1 bradykinin receptor.
| Trade Name | Firazyr |
|---|---|
| Common Name | Icatibant |
| Indication | hereditary angioedemas |
| Drug Class | Antiasthmatics (bradykinin antagonists) |
